Ivan A. Bespalov

Ivan A. Bespalov

Auto-generated profile, based on publicly available information

Ivan A. Bespalov

Genome Protection, Inc., Buffalo, New York

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
AVAlexandra V. Vylegzhanina
Alexandra V. Vylegzhanina
IBIvan A. Bespalov
Ivan A. Bespalov
KNKsenia A. Novototskaya-Vlasova
Ksenia A. Novototskaya-Vlasova
BHBrandon M. Hall
Brandon M. Hall
AGAnatoli S. Gleiberman
Anatoli S. Gleiberman
MGMarina Antoch and Andrei Gudkov
Marina Antoch and Andrei Gudkov
Long interspersed nuclear element-1 (LINE-1 or L1), the most abundant family of autonomous retrotransposons occupying over 17% of human DNA, is epigenetically silenced in normal tissues by the mechanisms involving p53 but is frequently derepressed in cancer, suggesting that L1-encoded proteins may act as tumor-associated antigens recognized by the immune system. In this study, we established an immunoassay to detect circulating autoantibodies against L1 proteins in human blood. Using this assay in >2,800 individuals with or without cancer, we observed significantly higher IgG titers against L1-encoded ORF1p and ORF2p in patients with lung, pancreatic, ovarian, esophageal, and liver cancers than in healthy individuals. Remarkably, elevated levels of anti–ORF1p-reactive IgG were observed in patients with cancer with disease stages 1 and 2, indicating that the immune response to L1 antigens can occur in the early phases of carcinogenesis. We concluded that the antibody response against L1 antigens could contribute to the diagnosis and determination of immunoreactivity of tumors among cancer types that frequently escape early detection. Significance: The discovery of autoantibodies against antigens encoded by L1 retrotransposons in patients with five poorly curable cancer types has potential implications for the detection of an ongoing carcinogenic process and tumor immunoreactivity.